Possible genetic explanation for why some lymphoma patients don't respond to treatment

October 30, 2015 by Henry Winter, Bloodwise

An important regulator that controls the ability of tumour cells to hide from the immune system in lymphoma patients, making them unlikely to respond to standard treatment, has been discovered by scientists at the University of Oxford.

Researchers funded by the blood cancer charity Bloodwise analysed tumour samples from individual with diffuse large B-cell lymphoma (DLBCL), alongside cell line models and data on treatment response and survival.

DLBCL, an aggressive cancer affecting , is diagnosed in around 5,000 people each year in the UK. There are several different subtypes of the disease, each of which differs in its response to chemotherapy.

The Oxford team found that high levels of shortened forms of a protein, known as FOXP1, in a patient's enable the cancer to evade the immune system, potentially nearly halving survival rates for these patients. The findings are published in the journal Leukemia.

The shortened form of the FOXP1 protein was shown to block molecular 'red flags' on the surface of lymphoma cells, that would normally present tumour markers to in the blood – thus blocking the body's natural defence against cancer.

An aggressive subtype of diffuse large B-cell lymphoma that affects around a half of all patients is known to have abundant shorter forms of the FOXP1 protein. There are a number of drugs currently being developed for this disease subtype, and these findings could add crucial information.

Professor Alison Banham, from the University of Oxford, said: "Scientists have been trying to understand the mechanism of this loss of immune system recognition for over a decade. Now we know that the FOXP1 protein has such an impact on how this type of lymphoma progresses, we can design drugs to switch off the FOXP1 gene in lymphoma cells and help patients' immune systems to fight their tumour."

When the scientists prevented the FOXP1gene from functioning in the laboratory, they found that levels of a group of proteins involved in cell interaction with the immune system were raised. Levels of one particular protein in this group, HLA-DRA (a major histocompatibility class II protein), rose significantly as levels of FOXP1 dropped in tumour cells.

The researchers then analysed the tumour profiles of 150 patients with DLBCL who had undergone standard treatment – a combination of chemotherapy and antibody drugs. While 72% of patients with high levels of the HLA-DRA protein survived for over five years after diagnosis, just 38% of patients with lower levels of the protein in their lymphoma cells survived that long. Scientists believe that blocking FOXP1can elevate HLA-DRA, which in turn helps the immune system to keep the lymphoma at bay.

Dr Matt Kaiser, Head of Research at Bloodwise, said: "Understanding how the FOXP1 enables tumour cells to hide from the could be a significant step in improving outcomes for hard-to-treat cases. Diffuse large B-cell lymphoma is the most common type of blood cancer and is responsible for a considerable loss of life each year in the UK. Whilst there's still a lot of work to do here, using knowledge of an individual's biology to tailor the treatment plan should ultimately bring significant benefits to patients, both in survival and quality of life."

FOXP1belongs to a group of proteins known as 'transcription factors', which control healthy cell development by switching genes on and off. As transcription factors regulate a vast array of different cell processes, any alteration to their function within can have radical effects on a cancer's behaviour. In breast cancer and other diseases the normal form of FOXP1 is thought to actually suppress tumour growth.

Explore further: Researchers show that genetic background regulates tumour differences

More information: P J Brown et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas, Leukemia (2015). DOI: 10.1038/leu.2015.299

Related Stories

Researchers show that genetic background regulates tumour differences

September 30, 2015
Researchers from Uppsala University, Sweden, and the Broad Institute, USA, have identified both similarities and differences between a single tumour type in multiple dogs breeds; a finding they believe parallels the situation ...

Cancer test predicts treatment outcome

October 2, 2015
University of Queensland researchers have announced a new tool in the fight against cancer, with the development of a world-first test that will direct treatment choices for patients with some forms of blood cancer.

Bacterium that causes Q fever linked to non-Hodgkin lymphoma

October 13, 2015
The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American ...

Blood vessel cells help tumours evade the immune system

August 24, 2015
A study by researchers at Sweden's Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The ...

Study shows promise of precision medicine for most common type of lymphoma

July 20, 2015
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype ...

Link between breast implants and cancer under investigation

October 6, 2014
An international research group including Viennese pathologist Lukas Kenner has reviewed cases of possible association between breast implants and a form of lymphoma that may develop tumors at a later stage. The researchers ...

Recommended for you

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

Aspirin and omega-3 reduce pre-cancerous bowel polyps

November 19, 2018
Both aspirin and a purified omega-3, called EPA, reduce the number of pre-cancerous polyps in patients found to be at high risk of developing bowel cancer, according to new research.

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.